Compare Adaptive Biotechnologies Corp (ADPT) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Energy Select Sector SPDR Fund — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Energy Select Sector SPDR Fund trades at $55.35. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Energy Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| ADPT | XLE | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | — |
52-Week High | $22.37 | $62.57 |
52-Week Low | $10.24 | $42.12 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
XLE trades at $53.13, down 0.17% on the day, with technical indicators showing a bearish trend as moving averages signal strong selling pressure. The ETF has gained 21% year-to-date, ranking among top-performing sector SPDRs according to ETF Trends on July 2, 2026. Recent news highlights oil price volatility and geopolitical developments affecting energy sector performance, while a dividend of $0.38 is scheduled for June 2026.
Outlook remains mixed with technical weakness offset by strong YTD performance. Investment opportunity exists for investors seeking energy sector exposure amid ongoing oil market volatility, though risks include geopolitical tensions and potential Federal Reserve rate hikes that could pressure the sector. The neutral oscillator reading suggests potential for near-term stabilization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
